GLP-1 Advisor | One Day MD

WEEKLY RESEARCH MONITOR EVIDENCE-FOCUSED AI IN HEALTHCARE Reporting period: 2–9 November 2026 Report date: 9 November 2026 Coverage: GLP-1 therapies, next-generation incretins, artificial intelligence, precision obesity treatment, clinical trials, pharmacovigilance and digital health. About this research monitor The GLP-1 & AI Research Monitor is an independent research initiative from OneDayMD and GLP-1 Advisor. Its purpose is to track developments at the intersection of metabolic medicine, pharmaceutical innovation, artificial intelligence and digital healthcare. The monitor covers both established GLP-1 receptor agonists and emerging therapies, while investigating how artificial intelligence may improve drug discovery, treatment selection, patient monitoring, medication adherence and safety surveillance. Rather than simply reporting pharmaceutical announcements, the objective is to evaluate what the evidence actually demonstrates, identify research...

By Dr. Frank Yap, MD · One Day Media Network · Published May 22, 2026 · Updated October 2026 ·  Disclosures: This article is educational and is not medical advice. Some product links are affiliate links (Amazon Associates) and may earn a commission at no extra cost to you; they did not influence the rankings or the evidence ratings. Dexcom is an investor in Oura, which appears in this article. Read the safety section before buying any glucose sensor. Quick Answer In October 2026, the only wearables that actually measure glucose are CGM sensors, and the over-the-counter options are Dexcom Stelo and Abbott Lingo (US, adults 18+ not on insulin). Rings and watches add context but are not FDA-authorized to measure glucose. A 2026 JAMA Internal Medicine review found no evidence that CGMs improve health in people without diabetes. On this page ...